FDA Inspection 1121547 — Erode Cancer Centre
The FDA completed an inspection of Erode Cancer Centre on February 28, 2020 in Thindal. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- February 28, 2020
- Fiscal Year
- 2020
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Thindal (India)
Additional Details
Clinical BA/BE